{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-291114","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2026-06-30T23:44:07+00:00","discovered_at":"2026-07-01T10:05:00.265115+00:00","generated_at":"2026-07-01T10:05:32.710348+00:00","sec_items":["2.01","3.03","5.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; shares to be delisted","bullets":["Total consideration ~USD$3.47M for 2,043,719 shares not already owned by Hanmi.","Premium of 28% over 30-day VWAP of C$1.88 on TSX.","All directors resigned effective June 30, 2026.","Common shares expected to be delisted from TSX on or about July 3, 2026.","Company to terminate reporting obligations in US and Canada."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-291114","json":"https://secwatch.observer/filing/0001193125-26-291114.json","markdown":"https://secwatch.observer/filing/0001193125-26-291114.md","text":"https://secwatch.observer/filing/0001193125-26-291114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000119312526291114/0001193125-26-291114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000119312526291114/d161768d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T10:05:32.710348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}